Monographie - Phenobarbital sodium

viimane versioon :
05/12/2025

Phenobarbital sodium

keemiline struktuur

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Carbital	Brasiilia
Fenemal	Rootsi
Fenobarb	India
Fenobarbital	Argentiina, Brasiilia, Ecuador, Kolumbia, Maroko, Rumeenia, Tšiili
Gardenal	Brasiilia, India, Maroko, Prantsusmaa, Suurbritannia, Tuneesia, Venetsueela
Luminal	Hispaania, Iraan, Saksamaa
Luminale	Itaalia
Luminalum	Poola
Noberbar	Jaapan
Phenobarbital sodium	Belgia, Iraan, Kanada, Suurbritannia, Sveits
Sominaletta	Egiptus
Unifenobarb	Brasiilia

Viited : Phenobarbital sodium

	tüüp	avaldamine
58	ajaleht	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
201	ajaleht	Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531.
226	ajaleht	Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295.
266	ajaleht	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
300	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	ajaleht	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
349	ajaleht	Nahata MC, Hipple TF, Strausbaugh SD. Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection. Am J Hosp Pharm 1986 ; 43: 384-385.
642	ajaleht	Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59.
660	ajaleht	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
921	ajaleht	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1057	ajaleht	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	ajaleht	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1412	ajaleht	Brett A, Riggs RM, Webster AA, Benner KW. Y-site stability of fosphenytoin and sodium phenobarbital. Int J Pharm Compound 1999 ; 3: 64-66.
1415	ajaleht	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1625	ajaleht	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1802	ajaleht	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1925	ajaleht	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1974	ajaleht	Chandler SW, Trissel LA, Weinstein SM Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
2090	ajaleht	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2262	ajaleht	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3379	ajaleht	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3408	ajaleht	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3501	Labor	Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics Pfizer 2011
3525	Labor	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3526	Labor	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3531	Labor	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3596	Labor	Chlorpromazine (Largactil®) - Summary of Product Characteristics Sanofi 2014
3631	Labor	Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit Aguettant 2016
3674	Labor	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3676	Labor	Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit Hospira 2014
4009	Labor	Droperidol - Résumé des Caractéristiques du Produit Panpharma 2017
4419	ajaleht	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4435	ajaleht	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4543	ajaleht	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4700	Labor	Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics AS Kalceks 2022
4742	ajaleht	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4837	ajaleht	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4845	ajaleht	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4888	ajaleht	Vo D, Robillard J, Lamoureux S, St-Jean I, Friciu M, Forest J.M, Leclair G. Stabilité du propofol, du rocuronium, du phénobarbital et du magnésium injectables reconditionnés en seringue pour les trousses d’aide médicale à mourir. Pharmactuel 2024 ; 57, 4: 127-133.
4924	ajaleht	Senarathna G, Strunk T, Petrovski M, Woodland S, Martinez J, Chuang V, Batty K. Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings EJHP 2023 2025;32:
5054	Labor	POLTEOFİLİN 400 MG/500 ML INJECTABLE SOLUTION FOR I.V. INFUSION - Summary of Product Characteristics. POLİFARMA İLAÇ SAN. VE TİC. A.Ş. 2018

Mentions Légales